Kezar Life Sciences, Inc. (KZR) Stock Profile — Insider Trades & Financials

Net Income-$14.5M

EPS$-5.67

Market Cap$54.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Christopher Kirk

CEO & Executive Director

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The companyâs lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Founded: 2015
Employees: 55
Headquarters

⚡

Core Efficiency

ROE?

-20.76%

ROA?

-18.98%

D/E Ratio?

0.09

📊

Profitability Ratios

Current Ratio?

11.52

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 10, 2026 (in 154 days)

Annual Report (10-K) — Based on filing pattern

Sep 10, 2026

Predicted10-K

Mar 27, 2026

10-KQ4 20254d after period end

Mar 27, 2026

10-KFY 202586d after period end

Nov 12, 2025

10-QQ3 20252d after period end

Aug 13, 2025

10-QQ2 20255d after period end

May 13, 2025

10-QQ1 20255d after period end

Mar 25, 2025

10-KQ4 20244d after period end

Mar 25, 2025

10-KFY 202584d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Loading company sections...

Kezar Life Sciences, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness